PO-1793: BioXmark liquid fiducials to enable radiotherapy tumor boosting in rectal cancer feasibility trial

The in-silico feasibility of dose escalated, hypofractionated radiotherapy for rectal cancer

“…Improving the localisation of the tumour on CBCT to guide online decision making may allow further refinement and margin reduction [36] . Radiopaque marker insertion in rectal cancer radiotherapy has been shown to be safe and feasible [37] , an approach that may work best in SCRT where treatment delivery is over five days with less tumour regression or migration.…”